AAAAAA

   
Results: 1-16 |
Results: 16
EFFECT OF SR121566A, A POTENT GP IIB-IIIA ANTAGONIST, ON THE HIT SERUM HEPARIN-INDUCED PLATELET-MEDIATED ACTIVATION OF HUMAN ENDOTHELIAL-CELLS
Authors: HERBERT JM SAVI P JESKE WP WALENGA JM
Citation: Jm. Herbert et al., EFFECT OF SR121566A, A POTENT GP IIB-IIIA ANTAGONIST, ON THE HIT SERUM HEPARIN-INDUCED PLATELET-MEDIATED ACTIVATION OF HUMAN ENDOTHELIAL-CELLS, Thrombosis and haemostasis, 80(2), 1998, pp. 326-331
PERSISTENCE OF THROMBOTIC COMPLICATIONS IN HEPARIN-INDUCED THROMBOCYTOPENIA PATIENTS AFTER HEPARIN WITHDRAWAL - PROPOSED MECHANISMS OF CONTINUED PLATELET ACTIVATION
Authors: WALENGA JM AHMAD S JESKE WP WOOD J AMIRAL J LEWIS BE
Citation: Jm. Walenga et al., PERSISTENCE OF THROMBOTIC COMPLICATIONS IN HEPARIN-INDUCED THROMBOCYTOPENIA PATIENTS AFTER HEPARIN WITHDRAWAL - PROPOSED MECHANISMS OF CONTINUED PLATELET ACTIVATION, Circulation, 98(17), 1998, pp. 4199-4199
EFFECT OF GLYCOPROTEIN IIB IIIA ANTAGONISTS ON THE HIT SERUM-INDUCED ACTIVATION OF PLATELETS/
Authors: JESKE WP WALENGA JM SZATKOWSKI E ERO M HERBERT JM HAAS S BAKHOS M
Citation: Wp. Jeske et al., EFFECT OF GLYCOPROTEIN IIB IIIA ANTAGONISTS ON THE HIT SERUM-INDUCED ACTIVATION OF PLATELETS/, Thrombosis research, 88(3), 1997, pp. 271-281
EFFICACY OF PENTASACCHARIDE IN A DOG-MODEL OF HEMODIALYSIS
Authors: HOPPENSTEADT DA JESKE WP WALENGA JM FU KD YANG LH ING T HERBERT JM FAREED J
Citation: Da. Hoppensteadt et al., EFFICACY OF PENTASACCHARIDE IN A DOG-MODEL OF HEMODIALYSIS, Thrombosis research, 88(2), 1997, pp. 159-170
BIOCHEMICAL AND PHARMACOLOGICAL RATIONALE FOR THE DEVELOPMENT OF A SYNTHETIC HEPARIN PENTASACCHARIDE
Authors: WALENGA JM JESKE WP BARA L SAMAMA MM FAREED J
Citation: Jm. Walenga et al., BIOCHEMICAL AND PHARMACOLOGICAL RATIONALE FOR THE DEVELOPMENT OF A SYNTHETIC HEPARIN PENTASACCHARIDE, Thrombosis research, 86(1), 1997, pp. 1-36
CLINICAL USEFULNESS OF 3 ASSAYS FOR THE LABORATORY DIAGNOSIS OF DOCUMENTED HEPARIN-INDUCED THROMBOCYTOPENIA - IS THERE A GOLD STANDARD
Authors: WALENGA JM FASANELLA AR JESKE WP ZAMAN S ARANHA R BAKHOS M
Citation: Jm. Walenga et al., CLINICAL USEFULNESS OF 3 ASSAYS FOR THE LABORATORY DIAGNOSIS OF DOCUMENTED HEPARIN-INDUCED THROMBOCYTOPENIA - IS THERE A GOLD STANDARD, Circulation, 96(8), 1997, pp. 213-213
GLYCOPROTEIN IIB IIIA INHIBITORS CAN PREVENT HEPARIN-MEDIATED PLATELET ACTIVATION IN HEPARIN-INDUCED THROMBOCYTOPENIA/
Authors: FAREED J YANG L JESKE WP HOPPENSTEADT D BLAKEMORE C LEWIS BE HAAS S WALENGA JM
Citation: J. Fareed et al., GLYCOPROTEIN IIB IIIA INHIBITORS CAN PREVENT HEPARIN-MEDIATED PLATELET ACTIVATION IN HEPARIN-INDUCED THROMBOCYTOPENIA/, Blood, 90(10), 1997, pp. 2984-2984
MOLECULAR-WEIGHT AND NATURAL SYNTHETIC SOURCE OF HEPARIN RELATED TO PLATELET ACTIVATION AND AGGREGATION IN HEPARIN-INDUCED THROMBOCYTOPENIA/
Authors: JAY A JESKE WP FASANELLA A WOOD J BAKHOS M WALENGA JM
Citation: A. Jay et al., MOLECULAR-WEIGHT AND NATURAL SYNTHETIC SOURCE OF HEPARIN RELATED TO PLATELET ACTIVATION AND AGGREGATION IN HEPARIN-INDUCED THROMBOCYTOPENIA/, Blood, 90(10), 1997, pp. 2988-2988
CROSS-REACTIVITY OF LOW-MOLECULAR-WEIGHT HEPARINS WITH ANTI-PF4-HEPARIN ANTIBODIES AS MEASURED USING THE SEROTONIN RELEASE ASSAY
Authors: JESKE WP HAAS S WOOD J FASANELLA A MESSMORE HL AMIRAL J BAKHOS M WALENGA JM
Citation: Wp. Jeske et al., CROSS-REACTIVITY OF LOW-MOLECULAR-WEIGHT HEPARINS WITH ANTI-PF4-HEPARIN ANTIBODIES AS MEASURED USING THE SEROTONIN RELEASE ASSAY, Blood, 90(10), 1997, pp. 2989-2989
EVALUATION OF PLATELET-FUNCTION FOLLOWING PHOTOCHEMOTHERAPY IN CHRONIC HEART LUNG REJECTION/
Authors: SILBERMAN S JESKE WP SZATKOWSKI E ROBINSON J WALENGA JM
Citation: S. Silberman et al., EVALUATION OF PLATELET-FUNCTION FOLLOWING PHOTOCHEMOTHERAPY IN CHRONIC HEART LUNG REJECTION/, Blood, 90(10), 1997, pp. 2995-2995
TISSUE FACTOR PATHWAY INHIBITOR (TFPI) AND A DIRECT FACTOR XA INHIBITOR (DX-9065A) BUT NOT A GLYCOPROTEIN IIB IIIA INHIBITOR (REOPRO(R)) ANTAGONIZE PLATELET ACTIVATION-INDUCED BY FACTOR XA AND TISSUE FACTOR/
Authors: KAISER B JESKE WP WALENGA JM FAREED J
Citation: B. Kaiser et al., TISSUE FACTOR PATHWAY INHIBITOR (TFPI) AND A DIRECT FACTOR XA INHIBITOR (DX-9065A) BUT NOT A GLYCOPROTEIN IIB IIIA INHIBITOR (REOPRO(R)) ANTAGONIZE PLATELET ACTIVATION-INDUCED BY FACTOR XA AND TISSUE FACTOR/, Blood, 90(10), 1997, pp. 3012-3012
COMPARISON OF WHOLE-BLOOD AND PLATELET-RICH PLASMA FOR A DIAGNOSTIC ASSAY OF HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) AS DETERMINED BY FLOW-CYTOMETRY
Authors: SZATKOWSKI E JESKE WP BAKHOS M WALENGA JM
Citation: E. Szatkowski et al., COMPARISON OF WHOLE-BLOOD AND PLATELET-RICH PLASMA FOR A DIAGNOSTIC ASSAY OF HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) AS DETERMINED BY FLOW-CYTOMETRY, Blood, 90(10), 1997, pp. 3111-3111
GLYCOPROTEIN IIB IIIA INHIBITORS POTENTIATE THE INHIBITION OF THROMBIN GENERATION BY FACTOR XA BUT NOT BY THROMBIN INHIBITORS/
Authors: KAISER B GLUSA E JESKE WP WALENGA JM FAREED J
Citation: B. Kaiser et al., GLYCOPROTEIN IIB IIIA INHIBITORS POTENTIATE THE INHIBITION OF THROMBIN GENERATION BY FACTOR XA BUT NOT BY THROMBIN INHIBITORS/, Blood, 90(10), 1997, pp. 3145-3145
SUPERIOR PERFORMANCE OF ECARIN CLOTTING TIME OVER APTT FOR THE MONITORING OF PEG-HIRUDIN ACTIVITY IN PLASMA
Authors: HAAS S ESSLINGER HU RUBSAMEN K JESKE WP WALENGA JM
Citation: S. Haas et al., SUPERIOR PERFORMANCE OF ECARIN CLOTTING TIME OVER APTT FOR THE MONITORING OF PEG-HIRUDIN ACTIVITY IN PLASMA, Blood, 90(10), 1997, pp. 3225-3225
COMPARATIVE ANTITHROMBOTIC ACTIONS OF HIRUDIN AND PEG-HIRUDIN IN ANIMAL-MODELS - DISCORDANCE BETWEEN CIRCULATING LEVELS AND ANTITHROMBOTIC EFFECT
Authors: WALENGA JM JESKE WP FU K YANG L BAKHOS M FAREED J
Citation: Jm. Walenga et al., COMPARATIVE ANTITHROMBOTIC ACTIONS OF HIRUDIN AND PEG-HIRUDIN IN ANIMAL-MODELS - DISCORDANCE BETWEEN CIRCULATING LEVELS AND ANTITHROMBOTIC EFFECT, Blood, 90(10), 1997, pp. 1315-1315
RELEVANCE OF CURRENT LABORATORY METHODS TO THE CLINICAL OUTCOME OF HEPARIN-INDUCED THROMBOCYTOPENIA - RESULTS OF THE ARG-911 TRIAL
Authors: WALENGA JM JESKE WP FASANELLA A LEWIS BE SCHWARZ R BAKHOS M
Citation: Jm. Walenga et al., RELEVANCE OF CURRENT LABORATORY METHODS TO THE CLINICAL OUTCOME OF HEPARIN-INDUCED THROMBOCYTOPENIA - RESULTS OF THE ARG-911 TRIAL, Blood, 90(10), 1997, pp. 2047-2047
Risultati: 1-16 |